Korean Lip Fillers Compared: Lipstar, Tesoro Rouge, Revolax and VOM

Reviewed against current FillersFairy inventory, named company or brand materials, CGBIO product documentation and general FDA filler-safety guidance. Last source review: August 1, 2026.

Quick answer: This Korean lip filler comparison separates lip-dedicated products from wider HA families. The reviewed Lipstar and Tesoro Rouge each add a colour-associated component alongside HA—anthocyanin and vitamin B12 respectively—while no comparable addition was identified in the reviewed Revolax or VOM materials. The exact Revolax or VOM model still requires verification.

Korean lip filler comparison poster showing Lipstar Tesoro Rouge Revolax and VOM product routes — Four comparison routes, with VOM represented as one three-model family rather than three separate brands.

Scope: this is a product-identity and procurement guide for professional clinic teams. It is not a patient-specific recommendation, injection protocol, dose guide, universal “best filler” ranking or substitute for the exact instructions for use (IFU), current local regulation and qualified clinical judgement.

What This Korean Lip Filler Comparison Can—and Cannot—Decide

A product name can answer a useful first question: is the item presented specifically as a lip product, or is it one model inside a wider HA family? It cannot, by itself, establish clinical suitability, handling, durability, authorization or a better result. Those conclusions require evidence attached to the exact product, version, intended use and market.

This comparison therefore separates five evidence levels. They are not interchangeable, and a lower level cannot be silently promoted into a higher one.

Evidence level	What it can support	What it cannot prove alone
Regulatory record	Exact-product status in a named jurisdiction and on a stated date.	Status in another country, another use or another model.
Company or brand information	Product identity, range structure, presentation and documented positioning.	Independent clinical superiority or market-wide authorization.
Peer-reviewed evidence	A defined product, material or outcome within the limits of a study.	A claim for every product sharing the brand or ingredient.
Brand positioning	How a product or family is organized and marketed.	Guaranteed feel, duration, safety or patient outcome.
Inventory fact	Which name, pack or selector is currently represented in the FillersFairy catalogue.	The legal label, IFU or regulatory status.

Korean Lip Fillers at a Glance

Product route	Dedicated lip naming?	Documented route reviewed	Added non-HA component	Current pack signal	Lidocaine signal	Evidence ceiling
Lipstar 1.2 mL	Yes	A Starpharmtec company listing names Lip Star as a lip filler for lip contour.	Anthocyanin 1 mg/mL with cross-linked HA 24 mg/mL; a named addition not identified in the reviewed conventional-family materials.	One 1.2 mL syringe in the reviewed listing.	Not established by the reviewed source; check the exact box.	Company product information plus catalogue fact—not a regulatory record.
Tesoro Rouge 1.1 mL	Yes	BNCÉRA lists it as “Tesoro Rouge Lip HA Filler” and records a February 2025 launch.	Cyanocobalamin (vitamin B12) 1 mg/mL with HA 26 mg/mL; a named addition not identified in the reviewed conventional-family materials.	Current FillersFairy presentation: 1 × 1.1 mL.	3 mg/mL in the BNC Global catalogue; confirm on the supplied label.	BNC Global catalogue plus official company positioning and inventory fact.
Revolax Fine / Deep	No; these are models in a wider family.	REVOLAX UK materials explicitly list lips for Deep, while a brand FAQ discusses both Fine and Deep lip routes.	No comparable tint ingredient identified in the reviewed Fine/Deep material.	1.1 mL for each reviewed model.	0.3% in the reviewed Fine and Deep materials.	Brand product information; Fine and Deep are not interchangeable.
VOM Light / Intensive / Volume	No; this is a three-model family.	CGBIO documentation separates fine-wrinkle, deep-wrinkle and volumizing/contouring tiers. Its comparison data identifies VOM O in a group of example areas that includes lips.	No comparable tint ingredient identified in the reviewed VOM document.	The current selector exposes Light, Intensive and Volume.	Confirm on the exact model label and applicable IFU.	CGBIO product document plus catalogue selector; not a family-wide lip claim.

Reading rule: Lipstar and Tesoro Rouge are the two lip-dedicated, HA-plus routes; Revolax and VOM are wider HA families that require an exact-model check.

Dedicated lip filler products compared with wider HA filler families that require an exact model check — A lip-specific name is an identification signal, not proof that the product is universally suitable or superior.

Dedicated Korean Lip Filler Products: Lipstar and Tesoro Rouge

Formula note: the reviewed Lipstar and Tesoro Rouge each pair HA with a named colour-associated component—anthocyanin 1 mg/mL and cyanocobalamin (vitamin B12) 1 mg/mL respectively. No comparable addition was identified in the reviewed Revolax Fine/Deep or VOM materials. This is a route distinction, not proof of a better clinical outcome.

Table of Contents

Lipstar 1.2 mL: a clearly named lip route

The Lipstar listing reviewed for this guide is unusually direct about product identity. The title names a lip filler and lip contour, while the product description lists one 1.2 mL syringe. It also reports cross-linked HA at 24 mg/mL and anthocyanin at 1 mg/mL. These are Starpharmtec company-listing facts hosted on TradeKorea, not independent clinical findings.

That distinction matters. The listing contains broader marketing statements about color, hydration and longevity, but a clinic should not turn them into guaranteed outcomes. Composition, storage, included accessories, lidocaine status, contraindications and legal eligibility still need to match the supplied box, current IFU and destination-market record.

Why a clinic may shortlist this route: it provides a dedicated lip-labelled 1.2 mL option with a distinct company-documented formula, making the product identity easy to separate from a generic HA family.

Tesoro Rouge 1.1 mL: a separate lip-specific Tesoro line

Tesoro Rouge should not be treated as another name for Tesoro Fine, Deep or Sub-Q. BNCÉRA’s current filler category lists “Tesoro Rouge Lip HA Filler,” and the company’s history page records its launch in February 2025. That supports the lip-specific product position and its place as a separate route inside the wider Tesoro portfolio.

Tesoro Rouge’s named added component is vitamin B12. BNC Baltic’s Tesoro Rouge product record lists HA 26 mg/mL, cyanocobalamin (vitamin B12) 1 mg/mL, lidocaine 3 mg/mL and one 1.1 mL syringe. It also describes a low- and high-molecular-weight HA combination. The current FillersFairy pack presentation matches one 1.1 mL syringe.

Vitamin B12 is an added component rather than the HA gel that creates filler volume. The documented formula does not by itself prove superior colour, collagen stimulation, durability, safety or patient outcomes.

Why a clinic may shortlist this route: it offers a BNC company-positioned lip HA product that is clearly separated from the general Tesoro filler grades.

Conventional Korean Lip Filler Families Require the Exact Model: Revolax and VOM

Revolax Fine and Deep are two different decisions

A brand-only search for “Revolax lip filler” is too broad. The REVOLAX UK material-properties table lists Fine and Deep as separate 1.1 mL products with 24 mg/mL HA and 0.3% lidocaine. The table explicitly names lips for Deep. A separate brand FAQ discusses both Fine and Deep in lip contexts while describing different positions inside the range.

That evidence supports a within-family question, not a universal answer. “Fine” cannot be translated automatically into “more natural,” and “Deep” does not mean “better projection” for every person. A practitioner must reconcile the exact model, its applicable documents, patient assessment and local eligibility. The existing Revolax Fine versus Deep guide carries the deeper model-selection intent; this page keeps the focus on how Revolax differs from dedicated lip-labelled products.

Why a clinic may shortlist this family: it provides a familiar three-grade HA structure in which Fine, Deep and Sub-Q remain visibly separate product identities.

VOM proves why the model name cannot be skipped

The current FillersFairy VOM sales page retains “Intensive” in its historical title and URL, but its product selector exposes three models: Light, Intensive and Volume. The page therefore represents a VOM family route, not an Intensive-only inventory signal.

CGBIO’s VOM document reports 20 mg/mL HA and describes a multi-layered phasic structure. It separates three product purposes: fine-wrinkle correction, deep-wrinkle correction and volumizing/contouring. A rheology section identifies its example as VOM O and includes lips among several typical areas for that compared profile. The document does not justify collapsing Light, Intensive and Volume into one interchangeable “VOM lip filler.”

This is the exact-model gate in practice. A clinic should read the name on the physical box, identify the model selected, check its applicable IFU and confirm that the destination-market record refers to the same version. If the storefront title, selector, box and source document do not align, the correct action is to pause and reconcile—not to infer the missing detail from the brand.

Why a clinic may shortlist this family: it supplies a three-model CGBIO HA route, but every decision must begin with Light, Intensive or Volume rather than the VOM name alone.

Clinic Selection Map: Start With the Product Route

This Korean lip filler clinic selection map helps a professional team structure a shortlist. It is an evidence and inventory workflow, not a treatment recommendation.

Clinic selection map for Lipstar Tesoro Rouge Revolax and the three VOM filler models — The route ends at a document gate, not at a universal winner.

Route 1

Need an explicitly lip-labelled SKU

Investigate Lipstar or Tesoro Rouge, then verify the exact box, formulation document and market status.

Route 2

Need a wider HA family with named lip routes

Investigate Revolax Fine and Deep as separate models; use the current model document rather than the family name alone.

Route 3

Need the VOM family

Identify Light, Intensive or Volume first. Do not use an old page title as proof of the selected model.

Stop gate

Documentation is incomplete

Request the current IFU, label and market record. “Do not shortlist yet” is a valid outcome.

Apply the same purchasing checks to every route

Check	Evidence to match	Stop condition
Exact identity	Brand, full product name, model and formulation suffix.	The selector, invoice, box or IFU names a different item.
Pack	Sealed unit, syringe count, fill volume and included accessories.	The physical unit does not match the ordered presentation.
Traceability	Supplier, invoice, lot, expiry, shipment and receiving record.	The supply trail or lot identity cannot be reconciled.
Market eligibility	Current regulator or conformity record naming the exact product where required.	Only a family-wide badge, old certificate or another market’s record is available.

What a Product Name or HA Concentration Does Not Prove

“Lip,” “Fine,” “Deep,” “Intensive” and “Volume” are useful identifiers inside their own product systems. They are not one shared cross-brand scale. A Fine product from one family is not automatically equivalent to Light from another, and an HA concentration cannot predict the entire clinical behavior of a gel.

Concentration alone does not establish softness, movement, projection, duration, ease of correction, safety or suitability for an individual patient. Cross-linking, gel structure, manufacturing method, test conditions, exact indication and clinical context all matter. Even a rheology value must be attached to the exact product and a comparable method before it can support a meaningful comparison.

The practical rule for any Korean lip filler is simple: use names and numbers to locate the correct document, not to replace it.

Ordering and Authenticity Checks for Korean Lip Fillers

Read the full label: verify the legal product name, model, formulation suffix and language version.
Match the IFU: confirm that the instructions belong to the same product and revision as the supplied box.
Confirm pack facts: reconcile syringe volume, syringe count, lidocaine wording, accessories, storage and single-use status.
Record traceability: retain the invoice, supplier identity, lot, expiry, shipment and receiving information.
Check the destination market: use the current applicable record; do not transfer an approval or certificate between models or countries.
Pause on conflict: a clear product photograph is helpful, but it cannot resolve contradictory documents or prove authenticity by itself.

For broader portfolio navigation, read the Korean dermal filler brand guide. For treatment-goal vocabulary rather than this product-evidence question, use the lip filler goals and product roles guide.

Safety and Professional-Use Boundary

Any Korean lip filler treatment remains a medical procedure. The US FDA’s general filler guidance identifies unintended injection into a blood vessel as the most concerning risk because reported complications include tissue necrosis, vision abnormalities including blindness, and stroke. It also advises patients not to self-inject and urges healthcare providers to inspect packages for authenticity.

This general safety source does not establish US approval for Lipstar, Tesoro Rouge, Revolax or VOM. Product status must be checked separately for the exact item and jurisdiction. Treatment belongs with an appropriately trained, licensed healthcare professional using an eligible, traceable product. See the site’s dermal filler safety information for the wider risk boundary.

Frequently Asked Questions

Does a lip filler need the word Lip in its product name?

No. A lip-specific name makes the product route easier to identify, but wider HA families can also contain models documented for lip use. The exact model, applicable IFU, local eligibility and practitioner assessment remain more important than the naming style.

How do Lipstar and Tesoro Rouge differ from conventional HA filler families?

Both are lip-labelled HA formulas with a named colour-associated addition: anthocyanin in the reviewed Lipstar and vitamin B12 in Tesoro Rouge. No comparable addition was identified in the reviewed Revolax Fine/Deep or VOM materials; the distinction does not prove a better clinical outcome.

Which Revolax models have a documented lip route?

The reviewed REVOLAX UK table explicitly lists lips for Deep, while a brand FAQ discusses both Fine and Deep for lip contexts. These are separate models with different positions inside the range, not interchangeable versions of one product.

Is VOM Intensive the same product as VOM Light?

No. The current sales-page selector shows Light, Intensive and Volume as three VOM models. CGBIO documentation also separates three product-purpose tiers. The historical Intensive title and URL should not be used to collapse the family into one model.

Can HA concentration alone identify the right Korean lip filler?

No. HA concentration is one formulation fact. It does not independently prove gel behavior, suitability, duration, safety or superiority. Use it only with the exact product label, technical information, IFU, current market record and qualified clinical assessment.

Continue by Exact Product, Not by Brand Alone

A useful Korean lip filler shortlist does not end with a winner. It ends with a small set of exact products whose labels, documents, pack configuration, traceability and market status can be reconciled. Start with Lipstar or Tesoro Rouge when dedicated lip naming matters; investigate Revolax or VOM when a wider family fits the clinic’s existing portfolio—but always finish at the model and document level.

Editorial note: company pages, product documents, inventory selectors and regulatory records can change. This comparison records the source position reviewed on August 1, 2026. Recheck the exact supplied product before procurement or clinical use.